2018 Report Package on Immuno-Oncology: Inhibitory & Stimulatory Immunomodulators - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 31, 2018--The “Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators” report has been added to ResearchAndMarkets.com’s offering.
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016.
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators.
C ompetitor projects are listed in a tabular format providing information on:Drug Codes Target / Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information
Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018
1a) PD-1 Receptor Antagonists
1b) PD-L1 Inhibitors
2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines
Report 2: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018
1a) CTLA-4 Receptor Antagonists
1b) LAG-3 Antagonists
1c) TIM-3 Antagonists
1d) TIGIT Antagonists
1e) Other Inhibitors of Negative Immune Checkpoints
2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines
Report 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators
1) Corporate Immune Checkpoint Activator R&D Pipelines
Report 4: Tumor Microenvironment Modulation via IDO, TGF-, CXCR4, CSF-1R, CD47-SIRP, adenosine pathway & STING 2018
1a) IDO & TDO Inhibitors
1b) TGF-beta Inhibitors
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
1g) Adenosine Pathway Modulation
1h) STING Agonists
2) Corporate Tumor Microenvironment Modulator R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/p3sgnd/2018_report?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005639/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs,Oncology,Immunosuppressive Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/31/2018 10:28 AM/DISC: 07/31/2018 10:28 AM